Published in Arthritis Rheum on January 01, 2008
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol (2010) 2.23
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Advances in human B cell phenotypic profiling. Front Immunol (2012) 1.41
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther (2010) 1.38
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol (2009) 1.32
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.25
The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 1.24
BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol (2009) 1.18
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther (2010) 1.18
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Targeting BAFF in autoimmunity. Curr Opin Immunol (2010) 1.08
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord (2013) 1.01
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Synovial tissues concentrate secreted APRIL. Arthritis Res Ther (2009) 0.88
Novel targeted therapies for autoimmunity. Curr Opin Immunol (2009) 0.87
The Interplay of IL-21 and BAFF in the Formation and Maintenance of Human B Cell Memory. Front Immunol (2012) 0.82
TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis (2011) 0.82
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol (2015) 0.81
[B-cell-targeted therapy in the treatment of autoimmune diseases]. Z Rheumatol (2009) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clin Exp Immunol (2009) 0.80
B-cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol (2009) 0.80
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther (2015) 0.80
B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) (2010) 0.79
Promising treatments of tomorrow for multiple sclerosis. Ann Indian Acad Neurol (2009) 0.79
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther (2015) 0.78
Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis. Biomed Res Int (2014) 0.78
Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol (2010) 0.78
B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis (2015) 0.78
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells. PLoS One (2013) 0.77
Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial. Arthritis Rheumatol (2015) 0.76
Development of a Novel BAFF Responsive Cell Line Suitable for Detecting Bioactive BAFF and Neutralizing Antibodies against BAFF-Pathway Inhibiting Therapeutics. Cells (2014) 0.75
B-cell targeting agents in the treatment of multiple sclerosis. Curr Treat Options Neurol (2013) 0.75
Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responses. J Rheumatol (2014) 0.75
Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia. J Biol Chem (2016) 0.75
[Novel B-cell directed strategies for the treatment of rheumatic diseases]. Z Rheumatol (2009) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM (1994) 5.23
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
The cryb mutation identifies cryptochrome as a circadian photoreceptor in Drosophila. Cell (1998) 4.81
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Classification of inflammatory arthritis by enthesitis. Lancet (1998) 4.48
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Generalised bone loss in patients with early rheumatoid arthritis. Lancet (1994) 3.93
The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum (2000) 3.85
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett (1997) 3.11
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum (1994) 2.74
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) (2001) 2.52
Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum (1998) 2.51
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum (2001) 2.49
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Stopping time: the genetics of fly and mouse circadian clocks. Annu Rev Neurosci (2001) 2.44
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol (1997) 2.30
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) (2000) 2.21
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis (2002) 2.11
Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature (1997) 2.09
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet (2001) 2.06
Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol (1998) 2.05
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet (1998) 1.98
Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol (1998) 1.97
Prescribing in the UK. Lancet (2001) 1.93
An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis (2005) 1.89
Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest (1997) 1.89
Subpopulations of primed T helper cells in rheumatoid arthritis. Arthritis Rheum (1993) 1.88
Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis (2008) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
An anatomical explanation for good-prognosis rheumatoid arthritis. Lancet (1999) 1.84
Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis (2004) 1.82
Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum (2007) 1.80
Classical versus non-renal Wegener's granulomatosis. Q J Med (1994) 1.79
Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology (Oxford) (1999) 1.78
The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum (1999) 1.78
Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum (1999) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum (1987) 1.70
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum (1999) 1.65
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Abnormal sulphur oxidation in systemic lupus erythematosus. Lancet (1992) 1.62
Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) (2003) 1.62
Acute aortitis and aortic incompetence due to systemic rheumatological disorders. Int J Cardiol (1991) 1.59
Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum (2008) 1.58
Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) (2005) 1.55
The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum (2004) 1.54
Rheumatological ultrasound. Rheumatology (Oxford) (2003) 1.54
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis (2013) 1.53
A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis (2014) 1.52
Pelvic insufficiency fractures in rheumatoid arthritis. Br J Rheumatol (1993) 1.52
Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum (1996) 1.52
A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol (2001) 1.51
The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy. Rheumatology (Oxford) (2003) 1.50
Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis (2003) 1.49
Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.48
Resistant rheumatoid arthritis clinics- a necessary development? Rheumatology (Oxford) (2000) 1.48
Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum (1994) 1.48
La Crosse virus small genome mRNA is made in the cytoplasm. J Virol (1986) 1.47
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis (2009) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer. Mol Cell Biol (1993) 1.46
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis (2004) 1.46
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J (1997) 1.45
From PREDs and open reading frames to cDNA isolation: revisiting the human chromosome 21 transcription map. Genomics (2001) 1.45
Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil). Rheumatology (Oxford) (1999) 1.45
Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum (2004) 1.45
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
The case for classification of polymyalgia rheumatica and remitting seronegative symmetrical synovitis with pitting edema as primarily capsular/entheseal based pathologies. J Rheumatol (2000) 1.44
The current status of ultrasonography in rheumatology. Rheumatology (Oxford) (1999) 1.44
The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations. Am J Hum Genet (1999) 1.44
Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum (2000) 1.44
Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics (1998) 1.43
Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum (1999) 1.42
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis (2008) 1.42
Wild-type circadian rhythmicity is dependent on closely spaced E boxes in the Drosophila timeless promoter. Mol Cell Biol (2001) 1.41